Mural Oncology Shares Data From ARTISTRY-3 Trial Designed To Evaluate Effects Of Less Frequent Intravenous Dosing Of Nemvaleukin Alfa In Advance Of ASCO Annual Meeting
Mural Oncology Shares Data From ARTISTRY-3 Trial Designed To Evaluate Effects Of Less Frequent Intravenous Dosing Of Nemvaleukin Alfa In Advance Of ASCO Annual Meeting
Mural Oncology 分享了 ARTISTRY-3 試驗的數據，該試驗旨在在 ASCO 年會之前評估降低靜脈注射頻率的 Nemvaleukin Alfa 的影響
Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3 and was generally well-tolerated at all doses tested, the company said.
該公司表示，Nemvaleukin在 ARTISTRY-3 中證明了其機制的藥效學證據，並且在所有測試劑量中總體耐受性良好。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。